Moderna changed its operating model. The company prepares for multiple product launches. These launches are anticipated in 2027 and 2028.
President Dr. Stephen Hoge assumes an expanded role. This role includes operational oversight. It covers Research & Development, Manufacturing, and Commercial operations. Moderna appointed Ester Banque as its new Chief Commercial Officer. She will lead the global commercial organization.
The changes align the company's three main franchises. These franchises are infectious diseases, intismeran (oncology), and rare diseases. The company prepares for the potential launch of up to three new vaccines. These include a flu and COVID combination shot, a seasonal flu vaccine, and a norovirus vaccine.